See more : Makara Mining Corp. (MAKA.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Roche Holding AG (RHHBY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Roche Holding AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- HLB Co., Ltd. (028300.KQ) Income Statement Analysis – Financial Results
- Sangoma Technologies Corporation (STC.V) Income Statement Analysis – Financial Results
- Beyon3D Ltd. (BYON.TA) Income Statement Analysis – Financial Results
- Dongil Industries Co.,Ltd. (004890.KS) Income Statement Analysis – Financial Results
- Jungheinrich Aktiengesellschaft (JGHHY) Income Statement Analysis – Financial Results
Roche Holding AG (RHHBY)
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.44B | 63.28B | 62.80B | 58.32B | 61.47B | 56.85B | 53.30B | 50.58B | 48.15B | 47.46B | 46.78B | 45.50B | 42.53B | 47.47B | 49.05B | 45.62B | 46.13B | 42.04B | 35.51B | 31.27B | 31.22B | 29.73B | 29.16B | 28.67B | 27.57B | 24.66B |
| Cost of Revenue | 16.36B | 20.40B | 19.65B | 16.18B | 18.35B | 17.27B | 18.18B | 16.18B | 15.46B | 13.38B | 11.95B | 12.18B | 11.94B | 13.29B | 14.62B | 13.66B | 13.74B | 10.62B | 9.30B | 7.18B | 8.32B | 8.43B | 8.34B | 9.16B | 8.87B | 7.90B |
| Gross Profit | 44.08B | 42.88B | 43.15B | 42.15B | 43.12B | 39.58B | 35.12B | 34.40B | 32.69B | 34.08B | 34.83B | 33.32B | 30.59B | 34.18B | 34.44B | 31.96B | 32.39B | 31.43B | 26.21B | 24.09B | 22.91B | 21.29B | 20.82B | 19.51B | 18.69B | 16.76B |
| Gross Profit Ratio | 72.94% | 67.77% | 68.72% | 72.26% | 70.14% | 69.62% | 65.89% | 68.01% | 67.89% | 71.81% | 74.46% | 73.24% | 71.92% | 72.00% | 70.20% | 70.05% | 70.21% | 74.75% | 73.80% | 77.03% | 73.37% | 71.63% | 71.41% | 68.04% | 67.81% | 67.96% |
| Research & Development | 14.20B | 16.02B | 14.80B | 13.01B | 12.77B | 12.09B | 11.29B | 11.53B | 9.58B | 9.90B | 9.27B | 9.55B | 8.33B | 10.03B | 9.87B | 8.85B | 8.39B | 6.59B | 5.71B | 5.09B | 4.77B | 4.26B | 3.89B | 3.95B | 3.78B | 3.41B |
| General & Administrative | 14.88B | 2.89B | 3.33B | 3.04B | 4.12B | 5.26B | 3.43B | 1.72B | 2.73B | 3.84B | 2.65B | 3.05B | 2.34B | 2.87B | 2.18B | 2.33B | 2.45B | 2.54B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
| Selling & Marketing | 0.00 | 9.64B | 9.92B | 9.57B | 10.96B | 10.11B | 9.85B | 9.14B | 8.81B | 8.66B | 8.37B | 8.54B | 8.05B | 9.49B | 9.48B | 9.17B | 9.33B | 10.86B | 9.51B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.88B | 12.53B | 13.25B | 12.61B | 15.08B | 15.37B | 13.27B | 10.86B | 11.54B | 12.50B | 11.02B | 11.59B | 10.39B | 12.36B | 11.65B | 11.50B | 11.78B | 13.40B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
| Other Expenses | -392.00M | -192.00M | -238.00M | -265.00M | -227.00M | -197.00M | -311.00M | -316.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 28.69B | 25.41B | 25.00B | 23.60B | 25.57B | 24.83B | 22.12B | 20.33B | 18.86B | 19.99B | 18.46B | 19.21B | 17.15B | 20.71B | 19.45B | 18.06B | 17.92B | 19.71B | 17.54B | 15.11B | 17.31B | 19.96B | 17.58B | 12.38B | 12.27B | 12.39B |
| Cost & Expenses | 45.05B | 45.81B | 44.65B | 39.78B | 43.92B | 42.10B | 40.30B | 36.51B | 34.32B | 33.37B | 30.40B | 31.39B | 29.09B | 34.01B | 34.06B | 31.72B | 31.67B | 30.33B | 26.84B | 22.29B | 25.63B | 28.39B | 25.92B | 21.54B | 21.15B | 20.29B |
| Interest Income | 183.00M | 67.00M | 342.00M | 16.00M | 99.00M | 30.00M | 30.00M | 22.00M | 24.00M | 34.00M | 27.00M | 32.00M | 73.00M | 51.00M | 179.00M | 698.00M | 1.07B | 788.00M | 423.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 997.00M | 690.00M | 419.00M | 553.00M | 791.00M | 744.00M | 765.00M | 958.00M | 1.11B | 1.18B | 1.33B | 2.00B | 2.01B | 2.55B | 2.44B | 214.00M | 281.00M | 315.00M | 264.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.46B | 3.82B | 4.45B | 4.57B | 4.31B | 3.60B | 3.89B | 3.95B | 3.64B | 2.62B | 2.38B | 2.42B | 2.37B | 2.55B | 2.69B | 2.65B | 2.54B | 2.44B | 1.01B | 1.61B | 1.51B | 1.52B | 1.55B | 2.85B | 2.45B | 2.07B |
| EBITDA | 18.54B | 20.86B | 22.86B | 23.08B | 21.70B | 22.51B | 21.19B | 17.91B | 16.74B | 19.13B | 18.99B | 16.24B | 16.29B | 16.27B | 15.50B | 16.48B | 18.12B | 15.34B | 9.68B | 10.58B | 7.10B | 2.86B | 4.80B | 27.57B | 8.87B | 6.44B |
| EBITDA Ratio | 30.67% | 34.02% | 36.40% | 38.58% | 35.37% | 31.95% | 31.52% | 35.38% | 35.44% | 35.03% | 39.76% | 37.30% | 38.48% | 34.69% | 37.52% | 36.12% | 37.31% | 33.97% | 27.26% | 33.84% | 22.75% | 9.60% | 16.46% | 34.80% | 32.19% | 26.13% |
| Operating Income | 15.40B | 17.48B | 18.16B | 18.54B | 17.55B | 14.77B | 13.00B | 14.07B | 13.82B | 14.09B | 16.38B | 14.13B | 13.45B | 13.49B | 12.28B | 13.92B | 14.47B | 11.73B | 8.67B | 8.98B | 5.59B | 1.34B | 3.25B | 7.13B | 6.42B | 4.37B |
| Operating Income Ratio | 25.47% | 27.62% | 28.91% | 31.79% | 28.55% | 25.98% | 24.40% | 27.82% | 28.71% | 29.69% | 35.01% | 31.04% | 31.63% | 28.41% | 25.03% | 30.52% | 31.36% | 27.90% | 24.41% | 28.71% | 17.91% | 4.49% | 11.13% | 24.87% | 23.29% | 17.72% |
| Total Other Income/Expenses | -1.32B | -1.15B | -757.00M | -578.00M | -934.00M | -621.00M | -755.00M | -1.06B | -1.83B | -1.58B | -1.70B | -1.97B | -1.57B | -2.28B | -2.05B | 237.00M | 836.00M | 857.00M | 133.00M | 506.00M | -711.00M | -4.53B | 1.52B | 2.34B | 1.13B | 1.08B |
| Income Before Tax | 14.08B | 16.33B | 17.40B | 17.97B | 16.61B | 14.15B | 12.25B | 13.01B | 11.99B | 12.52B | 14.68B | 12.32B | 11.89B | 11.21B | 10.23B | 14.16B | 15.30B | 12.59B | 8.97B | 9.49B | 4.88B | -3.19B | 4.76B | 9.47B | 7.56B | 5.45B |
| Income Before Tax Ratio | 23.29% | 25.80% | 27.70% | 30.80% | 27.03% | 24.89% | 22.98% | 25.72% | 24.90% | 26.37% | 31.37% | 27.08% | 27.94% | 23.62% | 20.86% | 31.04% | 33.17% | 29.94% | 25.25% | 30.33% | 15.63% | -10.75% | 16.33% | 33.02% | 27.41% | 22.11% |
| Income Tax Expense | 1.72B | 2.80B | 2.46B | 2.90B | 2.51B | 3.28B | 3.42B | 3.27B | 2.93B | 2.98B | 3.30B | 2.55B | 2.34B | 2.32B | 1.72B | 3.32B | 3.87B | 3.44B | 2.22B | 2.35B | 1.45B | 839.00M | 1.04B | 2.27B | 1.90B | 965.00M |
| Net Income | 11.50B | 12.42B | 13.93B | 14.30B | 13.50B | 10.50B | 8.63B | 9.58B | 8.86B | 9.33B | 11.16B | 9.43B | 9.34B | 8.67B | 7.78B | 8.97B | 9.76B | 7.88B | 5.92B | 6.61B | 3.07B | -4.03B | 3.70B | 8.65B | 5.76B | 4.39B |
| Net Income Ratio | 19.02% | 19.63% | 22.18% | 24.51% | 21.96% | 18.47% | 16.20% | 18.93% | 18.41% | 19.66% | 23.86% | 20.72% | 21.97% | 18.25% | 15.87% | 19.66% | 21.16% | 18.74% | 16.68% | 21.12% | 9.83% | -13.54% | 12.68% | 30.16% | 20.91% | 17.81% |
| EPS | 14.31 | 1.94 | 2.05 | 2.09 | 1.97 | 1.54 | 1.26 | 1.41 | 1.30 | 1.37 | 1.65 | 1.39 | 1.38 | 1.27 | 1.13 | 1.30 | 1.42 | 1.16 | 0.88 | 0.98 | 0.46 | -0.60 | 0.55 | 1.29 | 0.84 | 0.64 |
| EPS Diluted | 14.30 | 1.94 | 2.03 | 2.07 | 1.95 | 1.53 | 1.25 | 1.39 | 1.29 | 1.35 | 1.62 | 1.38 | 1.37 | 1.26 | 1.13 | 1.28 | 1.40 | 1.13 | 0.86 | 0.97 | 0.45 | -0.60 | 0.55 | 1.28 | 0.84 | 0.64 |
| Weighted Avg Shares Out | 803.49M | 6.40B | 6.80B | 6.84B | 6.85B | 6.83B | 6.82B | 6.82B | 6.81B | 6.79B | 6.78B | 6.78B | 6.79B | 6.84B | 6.86B | 6.88B | 6.87B | 6.82B | 6.76B | 6.72B | 6.71B | 6.71B | 6.72B | 6.72B | 6.90B | 6.90B |
| Weighted Avg Shares Out (Dil) | 804.00M | 6.40B | 6.88B | 6.92B | 6.91B | 6.88B | 6.88B | 6.88B | 6.90B | 6.90B | 6.90B | 6.84B | 6.81B | 6.86B | 6.87B | 6.89B | 6.90B | 6.90B | 6.88B | 6.80B | 6.80B | 6.71B | 6.90B | 6.76B | 6.90B | 6.90B |
Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environment
The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare. Roche is now integrating more than 20 artificial intelligence (AI) algorithms from eight new...
Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
Basel, 04 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new 48-week data for the investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib from the Phase II FENopta open-label extension (OLE) study at the 40th Congress of the...
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.
Roche Obtains Approval For its Rare Blood Disorder Drug in the EU
RHHBY gets approval for PiaSky for treating patients suffering from paroxysmal nocturnal hemoglobinuria in the EU.
Roche's PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
Basel, 27 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel recycling monoclonal antibody that inhibits the complement protein C5, for adults and adolescents (12 years of age...
First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company
PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute...
All You Need to Know About Roche Holding (RHHBY) Rating Upgrade to Strong Buy
Roche Holding (RHHBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for August 23rd
APELY, RHHBY, and SBSI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 23, 2024.
New Strong Buy Stocks for August 23rd
RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.
Best Value Stocks to Buy for August 23rd
RHHBY, SBSI, and FCCO made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 23, 2024.
Source: https://incomestatements.info
Category: Stock Reports